Resmed Q1 2027 earnings
Revenue growth slowed to 6% with a 30 bp gross margin expansion, while EPS rose 23% driven by margin improvement and share count reduction.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $1.415B | +6.0% | — | Ex. 99.1, income statement |
| EPS (GAAP) | $2.92 | +23.0% | — | Ex. 99.1, income statement |
| EPS (adjusted) | $2.91 | +14.0% | — | Ex. 99.1, income statement |
| Net income | $418M | +20.0% | — | Ex. 99.1, income statement |
| Adj. EBITDA | $506M | +5.0% | — | Ex. 99.1, income statement |
| Adj. EBITDA margin | 35.8% | -0.3 pp | — | Ex. 99.1, income statement |
Revenue breakdown
not stated in the 8-K
Margins and costs
- Gross margin 61.5% (prior 61.2%, change +30 bps)
- Operating expenses $417.6M (+12.0% YoY)
- One-offs in the quarter Restructuring and business transformation expenses: $29M; Acquisition and divestment related expenses: $10M; Gain on divestment of subsidiary: $55M; Income tax effect of interest income on tax refunds: $12M
- Effective tax rate 22.4% (prior 22.0%)
- Non-GAAP bridge Adds back amortization of acquired intangibles, restructuring and business transformation expenses, acquisition and divestment related expenses, gains on divestment of subsidiaries, and associated tax effects.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Operating cash flow | $422M | $455M | $457M | -8.0% |
| Free cash flow | $374M | $404M | $414M | -10.0% |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Non-GAAP diluted earnings per share | $10.80 - $11.20 | $10.43 - $10.43 | +3.4% - +7.4% |
What drove it
- Revenue story Revenue grew 6% year-over-year, with non-GAAP core constant currency revenue growth of 7%.
- EPS story EPS increased 23% driven by higher margins and a 2.4% reduction in diluted shares outstanding.
- One-off check Gain on divestment of subsidiary ($55M) and restructuring and business transformation expenses ($29M) are one-time items.
The good
- Non-GAAP gross margin expanded 50 bps YoY to 62.5%
- Non-GAAP diluted EPS grew 14% YoY to $2.91
- Free cash flow of $374M returned more than $1 billion to shareholders
The bad
- GAAP revenue growth slowed to 6% from 9% YoY
- Operating cash flow declined 8% YoY to $422M
- Free cash flow declined 10% YoY to $374M
The ugly
- none
Open questions
- The release does not provide specific revenue or margin guidance for the full fiscal year 2027.
- The filing does not disclose the specific proceeds or strategic rationale for the divestiture of MatrixCare.
Full release
Earnings: RMD — filed 2026-10-29
Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027
Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
SAN DIEGO, October 29, 2026 – Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended September 30, 2026.
“We began fiscal year 2027 with a strong first quarter, driven by continued global demand for our sleep and breathing health solutions and ongoing execution across our business,” said Resmed’s Chairman and CEO, Mick Farrell. “Year over year, we grew core constant currency revenue 7%, expanded non-GAAP gross margin by 50 basis points, and increased non-GAAP earnings per share by 14%. Our strong free cash flow and the proceeds from our divestiture of MatrixCare enabled us to both invest in innovation and return more than $1 billion to shareholders during the quarter.”
“Looking ahead to the rest of fiscal year 2027, we will continue to build our core sleep and breathing health businesses by extending the reach of our digital health ecosystem and connecting more of the people worldwide who need care with life-saving treatment delivered right in their own home.”
Other Business and Operational Highlights
Financial Results and Operating Metrics
(Unaudited; $ in millions, except for per share amounts)
Discussion of First Quarter Results
All comparisons are to the prior year period unless otherwise noted
Fiscal Year 2027 guidance
Dividend program
The Resmed board of directors today declared a quarterly cash dividend of $0.66 per share. The dividend will have a record date of November 12, 2026, payable on December 17, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian
Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares.
The ex-dividend date will be November 11, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from November 11, 2026, through November 12, 2026, inclusive.
Webcast details
Resmed will discuss its first quarter fiscal year 2027 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on Resmed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q1 2027 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately three hours after the webcast by dialing
+1 877-660-6853 (U.S.) or
+1 201-612-7415 (outside
U.S.) and entering the passcode 13762822. The telephone replay will be available until November 12, 2026.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our
AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
Safe harbor statement
Financial statements
Income Statement
Three Months Ended — (Unaudited; $ in millions, except for per share amounts)
| Three Months Ended – September 30, 2026 | Three Months Ended – September 30, 2025 | Three Months Ended – % Change | Three Months Ended – Constant Currency (A) | |
|---|---|---|---|---|
| Revenue | 1,415 | 1,336 | 6.0% | 6.0% |
| Gross margin (D) | 61.5% | 61.2% | 30 bps | |
| Non-GAAP gross margin (B) | 62.5% | 62.0% | 50 bps | |
| Research and development expenses (D) | 103 | 89 | 15.0% | 13 |
| Non-GAAP research and development expenses (B) | 102 | 87 | 16.0% | 14 |
| Selling, general, and administrative expenses (D) | 315 | 282 | 12.0% | 11 |
| Non-GAAP selling, general, and administrative expenses(B) | 276 | 259 | 6.0% | 6 |
| Income from operations | 453 | 447 | 1.0% | |
| Operating margin | 32.0% | 33.4% | (140) bps | |
| Non-GAAP income from operations (B) | 506 | 482 | 5.0% | |
| Non-GAAP operating margin (B) | 35.8% | 36.1% | (30) bps | |
| Net income | 418 | 349 | 20.0% | |
| Non-GAAP net income (B) | 418 | 375 | 12.0% | |
| Diluted earnings per share | 2.92 | 2.37 | 23.0% | |
| Non-GAAP diluted earnings per share (B) | 2.91 | 2.55 | 14.0% | |
| Operating cash flow | 422 | 457 | -8.0% | |
| Free cash flow (C) | 374 | 414 | -10.0% |
Income Statement
Three Months Ended — (Unaudited; $ in thousands, except for per share amounts)
| Three Months Ended – September 30, 2026 | Three Months Ended – September 30, 2025 | |
|---|---|---|
| Net revenue | 1,414,814 | 1,335,582 |
| Cost of sales (2) | 544,247 | 517,918 |
| Gross profit (2) | 870,567 | 817,664 |
| Research and development (2) | 102,860 | 89,479 |
| Selling, general, and administrative (2) | 314,723 | 281,648 |
| Total operating expenses | 417,583 | 371,127 |
| Income from operations | 452,984 | 446,537 |
| Other income (expenses), net: | ||
| Interest (expense) income, net | 16,384 | 8,793 |
| Gain (loss) attributable to equity method investments | 1,884 | 1,489 |
| Gain (loss) on equity investments | 5,719 | -6,190 |
| Other, net | 62,184 | -3,836 |
| Total other income (expenses), net | 86,171 | 256 |
| Income before income taxes | 539,155 | 446,793 |
| Income taxes | 120,742 | 98,257 |
| Net income | 418,413 | 348,536 |
| Basic earnings per share | 2.93 | 2.38 |
| Diluted earnings per share | 2.92 | 2.37 |
| Non-GAAP diluted earnings per share (1) | 2.91 | 2.55 |
| Basic shares outstanding | 142,989 | 146,182 |
| Diluted shares outstanding | 143,411 | 146,899 |
Income Statement
Three Months Ended — measures are reconciled to their most directly comparable GAAP financial measures below (in millions, except percentages):
| Three Months Ended – September 30, 2026 | Three Months Ended – September 30, 2025 | |
|---|---|---|
| GAAP total revenue growth | 6.0% | 9.0% |
| Impact of: | ||
| Acquisitions/divestitures (A) | 1 | |
| Effect of foreign currency fluctuations (A) | -1 | |
| Non-GAAP core constant currency total revenue growth | 7.0% | 8.0% |
Income Statement
Three Months Ended September 30, 2026 — (Unaudited; $ in millions, except for per share amounts)
| Three Months Ended September 30, 2026 – Gross profit | Three Months Ended September 30, 2026 – Research and development expenses | Three Months Ended September 30, 2026 – Selling, general, and administrative expenses | Three Months Ended September 30, 2026 – Income from operations | Three Months Ended September 30, 2026 – Total other income (loss), net | Three Months Ended September 30, 2026 – Income tax expense | Three Months Ended September 30, 2026 – Net income | Three Months Ended September 30, 2026 – Diluted earnings per share | |
|---|---|---|---|---|---|---|---|---|
| GAAP | 871 | 103 | 315 | 453 | 86 | 121 | 418 | 2.92 |
| Amortization of acquired intangibles | 5 | -8 | 14 | 4 | 10 | 0.07 | ||
| Restructuring and business transformation expenses | 8 | -1 | -20 | 29 | 7 | 22 | 0.16 | |
| Acquisition and divestment related expenses | -10 | 10 | 10 | 0.07 | ||||
| Gain on divestment of subsidiary | -62 | -7 | -55 | -0.38 | ||||
| Income tax effect of interest income on tax refunds | -12 | 12 | 0.07 | |||||
| Non-GAAP (A) | 884 | 102 | 276 | 506 | 24 | 113 | 418 | 2.91 |
Income Statement
Three Months Ended September 30, 2025 (in thousands)
| Three Months Ended September 30, 2025 – As previously reported | Three Months Ended September 30, 2025 – Restructuring and business transformation expenses | Three Months Ended September 30, 2025 – Amortization of acquired intangibles | Three Months Ended September 30, 2025 – As reclassified | |
|---|---|---|---|---|
| Cost of sales - Sleep and Breathing Health products | 456,118 | 3,156 | 1,420 | 460,694 |
| Cost of sales - Residential Care Software | 50,823 | 6,401 | 57,224 | |
| Cost of sales (exclusive of amortization shown separately below) | 506,941 | 3,156 | 7,821 | 517,918 |
| Amortization of acquired intangible assets - Sleep and Breathing Health products | 1,420 | -1,420 | ||
| Amortization of acquired intangible assets - Residential Care Software | 6,401 | -6,401 | ||
| Amortization of acquired intangible assets | 7,821 | -7,821 | $— | |
| Total cost of sales | 514,762 | 3,156 | 517,918 | |
| Gross profit | 820,820 | -3,156 | 817,664 | |
| Research and development | 87,323 | 2,156 | 89,479 | |
| Selling, general, and administrative | 259,194 | 10,498 | 11,956 | 281,648 |
| Amortization of acquired intangible assets | 11,956 | -11,956 | ||
| Restructuring expenses | 15,810 | -15,810 | ||
| Total operating expenses | 374,283 | -3,156 | 371,127 | |
| Income from operations | 446,537 | 446,537 |
Income Statement
Three Months Ended March 31, 2026 — (Unaudited; $ in thousands)
| Three Months Ended March 31, 2026 – As previously reported | Three Months Ended March 31, 2026 – Amortization of acquired intangibles | Three Months Ended March 31, 2026 – As reclassified | |
|---|---|---|---|
| Cost of sales - Sleep and Breathing Health products | 481,722 | 1,421 | 483,143 |
| Cost of sales - Residential Care Software | 50,855 | 6,429 | 57,284 |
| Cost of sales (exclusive of amortization shown separately below) | 532,577 | 7,850 | 540,427 |
| Amortization of acquired intangible assets - Sleep and Breathing Health products | 1,421 | -1,421 | |
| Amortization of acquired intangible assets - Residential Care Software | 6,429 | -6,429 | |
| Amortization of acquired intangible assets | 7,850 | -7,850 | $— |
| Total cost of sales | 540,427 | 540,427 | |
| Gross profit | 890,979 | 890,979 | |
| Research and development | 94,267 | 94,267 | |
| Selling, general, and administrative | 285,655 | 11,247 | 296,902 |
| Amortization of acquired intangible assets | 11,247 | -11,247 | |
| Total operating expenses | 391,169 | 391,169 | |
| Income from operations | 499,810 | 499,810 |
Income Statement
Three Months Ended June 30, 2026 — (Unaudited; $ in thousands)
| Three Months Ended June 30, 2026 – As previously reported | Three Months Ended June 30, 2026 – Amortization of acquired intangibles | Three Months Ended June 30, 2026 – As reclassified | |
|---|---|---|---|
| Cost of sales - Sleep and Breathing Health products | 539,975 | 2,011 | 541,986 |
| Cost of sales - Residential Care Software | 54,155 | 6,290 | 60,445 |
| Cost of sales (exclusive of amortization shown separately below) | 594,130 | 8,301 | 602,431 |
| Amortization of acquired intangible assets - Sleep and Breathing Health products | 2,011 | -2,011 | |
| Amortization of acquired intangible assets - Residential Care Software | 6,290 | -6,290 | |
| Amortization of acquired intangible assets | 8,301 | -8,301 | $— |
| Total cost of sales | 602,431 | 602,431 | |
| Gross profit | 861,216 | 861,216 | |
| Research and development | 105,726 | 105,726 | |
| Selling, general, and administrative | 296,283 | 10,499 | 306,782 |
| Amortization of acquired intangible assets | 10,499 | -10,499 | |
| Total operating expenses | 412,508 | 412,508 | |
| Income from operations | 448,708 | 448,708 |
Balance Sheet
(Unaudited; $ in thousands)
| September 30, 2026 | June 30, 2026 | |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | 1,010,742 | 1,469,234 |
| Accounts receivable, net | 972,498 | 1,036,233 |
| Inventories | 1,021,358 | 945,805 |
| Prepaid expenses and other current assets | 504,323 | 416,081 |
| Assets held for sale | 457,386 | |
| Total current assets | 3,508,921 | 4,324,739 |
| Non-current assets: | ||
| Property, plant, and equipment, net | 601,787 | 581,829 |
| Operating lease right-of-use assets | 196,688 | 153,167 |
| Goodwill and other intangibles, net | 3,350,913 | 3,362,312 |
| Deferred income taxes and other non-current assets | 553,502 | 543,903 |
| Total non-current assets | 4,702,890 | 4,641,211 |
| Total assets | 8,211,811 | 8,965,950 |
| Current liabilities: | ||
| Accounts payable | 320,677 | 308,923 |
| Accrued expenses | 480,166 | 494,921 |
| Operating lease liabilities, current | 31,527 | 29,141 |
| Deferred revenue | 171,647 | 162,911 |
| Income taxes payable | 160,228 | 98,108 |
| Short-term debt | 159,975 | 259,950 |
| Liabilities held for sale | 41,156 | |
| Total current liabilities | 1,324,220 | 1,395,110 |
| Non-current liabilities: | ||
| Deferred revenue | 174,209 | 170,951 |
| Deferred income taxes | 62,651 | 64,640 |
| Operating lease liabilities, non-current | 169,447 | 137,413 |
| Other long-term liabilities | 283,965 | 213,028 |
| Long-term debt | 249,629 | 399,415 |
| Total non-current liabilities | 939,901 | 985,447 |
| Total liabilities | 2,264,121 | 2,380,557 |
| Stockholders’ equity | ||
| Common stock | 764 | 764 |
| Additional paid-in capital | 2,133,418 | 2,190,614 |
| Retained earnings | 7,578,580 | 7,255,121 |
| Treasury stock | -3,633,335 | -2,778,591 |
| Accumulated other comprehensive loss | -131,737 | -82,515 |
| Total stockholders’ equity | 5,947,690 | 6,585,393 |
| Total liabilities and stockholders’ equity | 8,211,811 | 8,965,950 |
Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding Resmed’s projections of future revenue or earnings, expenses, results of operations, new product development, new product launches, new markets for its products, the integration of acquisitions and success of strategic initiatives, including divestitures, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in Resmed’s periodic reports on file with the U.S. Securities & Exchange Commission. Resmed does not undertake to update its forward-looking statements. – More – RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(Unaudited; $ in thousands, except for per share amounts) – More – RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(Unaudited; $ in thousands) – More – RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(Unaudited; $ in thousands) – More – RESMED INC. AND SUBSIDIARIES
Reconciliation of Non-GAAP Financial
Measures
(Unaudited; $ in millions, except for per share amounts)
In addition to financial information prepared in accordance with GAAP, we use certain non-GAAP financial measures, such as non-GAAP core constant currency basis, non-GAAP gross profit, non-GAAP gross margin, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, and non-GAAP... (truncated)the performance of our business. We believe that these non-GAAP financial measures, when reviewed in conjunction with
GAAP financial measures, can provide investors better insight when evaluating our performance from core operations and can provide more consistent financial reporting across periods. For these reasons, we use non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. These non-GAAP financial measures should be considered in addition to, and not superior to or as a substitute for, GAAP financial measures. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under
GAAP.
Non-GAAP financial measures as presented herein may not be comparable to similarly titled measures used by other companies.
The non-GAAP financial measures included in this release and the accompanying tables (including within the tables that provide our detailed reconciliations to the corresponding GAAP financial measures) are adjusted for the impact of acquisitions and divestitures, amortization of acquired intangibles, restructuring and business transformation expenses, acquisition and divestment-related expenses, gains on divestment of subsidiaries, and associated tax effects, in addition to the tax effect of interest and penalties on tax refunds.
We have not included a reconciliation of forward-looking non-GAAP financial measures where we are unable to provide a meaningful or accurate calculation or estimation of reconciling items, and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the occurrence and the financial impact of various items that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Forward-looking non-GAAP financial measures provided without the most directly comparable GAAP financial measures may vary materially from the corresponding GAAP financial measures.
Non-GAAP measures are reconciled to their most directly comparable GAAP financial measures below (in millions, except percentages):
RESMED INC. AND SUBSIDIARIES
Reconciliation of Non-GAAP Financial
Measures
(Unaudited; $ in millions, except for per share amounts)
RESMED INC. AND SUBSIDIARIES
Revenue by Product and Region
(Unaudited; $ in millions) – End – RESMED INC. AND SUBSIDIARIES
Reclassification of Prior-period Amounts
(Unaudited;
$ in thousands)
During the first quarter of fiscal year 2027, we revised the presentation of restructuring expenses and amortization of acquired intangibles in our condensed consolidated statements of operations. Restructuring expenses, which were previously presented as a separate line item within operating expenses, are now classified within cost of sales, research and development expenses, and selling, general and administrative expenses based on the function of the associated costs. In connection with this change, we renamed “restructuring expenses” as “restructuring and business transformation expenses” to reflect the broader nature of the costs included within this category. Amortization of acquired intangibles relating to cost of sales is no longer presented as a separate line item within cost of sales. Amortization of acquired intangibles relating to operating expenses are now classified within selling, general and administrative expenses.
Prior-period amounts have been reclassified to conform to the current-period presentation. The reclassifications had no effect on previously reported income from operations, income before income taxes, net income, earnings per share or cash flows. The following table reconciles previously reported amounts to the revised presentation (in thousands):
RESMED INC. AND SUBSIDIARIES
Reclassification of Prior-period Amounts
(Unaudited;
$ in thousands)
The following tables reconcile previously reported quarterly 2026 amounts to the revised presentation (in thousands):
RESMED INC. AND SUBSIDIARIES
Reclassification of Prior-period Amounts
(Unaudited;
$ in thousands)
RESMED INC. AND SUBSIDIARIES
Reclassification of Prior-period Amounts
(Unaudited;
$ in thousands)